Jinyu Biotechnology Co., Ltd., founded in 1958, is a listed company, specializing in the research and development, production and sales of foot-and-mouth disease cell suspension culture inactivated vaccine, swine fever live vaccine and other drugs
Jinyu Biotechnology Co., Ltd. (formerly Inner Mongolia Jinyu Group Co., Ltd.) was established in March 1993 with a registered capital of 572829860 yuan and listed on the Shanghai Stock Exchange in January 1999 with the stock code: 600201.
As of the end of September 2013, it has a total capital of 1.78 billion yuan and 983 employees.
Jinyu adheres to the corporate vision of "committed to health and creating a better life", pursues the core values of "Jingui people-oriented, Yugaohu Yifei", continues to carry out management, technology and product innovation, and continuously enhances its core competitiveness.
In 2008, it overcame the technical difficulties of cell suspension culture and took the lead in launching the first foot-and-mouth disease suspension culture production line in China, filling the domestic gap and leading the industrial upgrading;In 2012, three standards were formulated for the industry for the foot-and-mouth disease vaccine antigen content, heteroprotein content, antigen and heteroprotein detection.
Jinyu Biotechnology Industrial Park plans to build a high-standard foot-and-mouth disease suspension culture production line, a brucellosis vaccine production line and a national high-level biosafety laboratory, and takes the initiative to take the historical mission of promoting product and technological innovation in the domestic biopharmaceutical industry.
Yesterday is history, today is a new beginning. In the face of the fierce competition of globalization, Jin Yu will live up to expectations and live up to the trust of the times. All Jinyu people will practice the core value concept of "responsibility, innovation and value", be responsible, enterprising and innovative, keep improving, make persistent efforts, devote themselves to the biopharmaceutical industry, and create greater value for employees, shareholders, customers and society.
